1. Background {#sec0005}
=============

An average of 37 million people in the world are living with Human Immunodeficiency Virus (HIV) ([@bib0280]). The infection if untreated results in acquired immunodeficiency syndrome (AIDS) which has resulted in the death of over 35 million lives since the epidemic started ([@bib0250]). Albeit, access to effective combination antiretroviral therapy (cART) has resulted in a significant reduction in AIDS-related morbidity and mortality. More so, UNAIDS targets a decrease from 1 million AIDS-related death in 2016 to 500,000 in 2020, by ensuring that at least 30 million people living with HIV are on cART ([@bib0255]).

The cART which involves the concurrent use of a combination of three or more antiretroviral drugs to suppress HIV replication ([@bib0280]) has reduced HIV to a manageable disease however, the reports of their adverse effects resulting in organo-toxicities, gross neurological and cognitive dysfunction among HIV infected patients and experimental animals have become a growing concern ([@bib0235]; [@bib0005]). Though HIV infects microglial cells leading to severe tissue damage in the central nervous system (CNS); cognitive dysfunction, learning and memory impairments (leading to dementia), and other neurological disorders were observed among patients on cART ([@bib0115]). Whether or not the neurological impairments are associated with cART or the virus itself remains unclear ([@bib0235]). It's been reported that cART penetrates the blood brain barrier, thus, chronic dependence has a high probability of affecting neurological activities ([@bib0210]). In addition, [@bib0030] reported that cART causes neuroinflammation in HIV infected patients by inducing microglial reaction especially in the hippocampus which mediates several higher brain functions, such as learning, memory, and spatial coding.

The oxidative stress which is a vital precursor of most diseases is upregulated in continuous and prolonged use of cART ([@bib0015]). This may contribute to the myriads of HIV associated neurocognitive disorders (HAND) ([@bib0025]; [@bib0115]; [@bib0300]). Hence, the upregulation of endogenous antioxidants may be a plausible mechanism to antagonize these drawbacks ([@bib0240]).

The use of bioflavonoids in attenuating oxidative stress induced diseases has generated so much interest, as they possess the ability to capture reactive oxygen species (ROS) such as superoxide, hydroxyl and lipid radicals ([@bib0205]). Flavonoids which are rich phytochemical extracts improve memory, learning and other cognitive functions ([@bib0195]). They also protect neurons from neurotoxins by enhancing existing neuronal function, suppressing neuroinflammation and by stimulating neuronal regeneration ([@bib0285]) as seen in the treatment of neurodegenerative disorders ([@bib0265]).

Both Naringenin and Quercetin are major free radical scavengers. Quercetin, one of the most widely distributed flavonoids in fruits and vegetables (eg. red onion, common onion, cranberry, and blueberry) has been reported to inhibit the oxidation of other molecules and hence is classified as an antioxidant ([@bib0225]). Naringenin, commonly found in grape fruits has been reported by [@bib0005] to attenuate EFV/FTC/TDF induced toxicity in rats. These bioflavonoids have also been reported to boost endogenous antioxidants and possess anti-apoptotic properties ([@bib0155]; [@bib0180]; [@bib0215]). The ability of these flavonoids/metabolites to penetrate the blood-brain barrier (BBB) seems to be dependent on their lipophilicity and their interactions with specific efflux transporters (such as p-glycoproteins) expressed in the BBB ([@bib0305]).

Hence, this study is aimed at exploring the therapeutic potential of Naringenin and Quercetin on cART induced Hippocampal disorders.

2. Materials and methods {#sec0010}
========================

2.1. Chemicals, reagents and drugs {#sec0015}
----------------------------------

Quercetin (Cat No: Q4951-100 G), Naringenin (Cat No: W530098-500 G), and Dimethyl sulfoxide (DMSO) (Cat No: 317275-500ML), were purchased from Sigma Aldrich South Africa. While cART a combination of Efavirenz 600 mg, Lamivudine 300 mg, Tenofovir Disoproxil Fumarate 300 mg, manufactured by MACLEODS pharmaceuticals, India was provided by the AIDS Prevention Initiative in Nigeria (APIN) center at Lagos University Teaching Hospital (LUTH).

2.2. Experimental animals and design {#sec0020}
------------------------------------

Seventy (70) adult male Wistar rats with weights ranging from 225 to 260 g were used for this study. The animals were acclimatized for three weeks in the Animal House, Department of Anatomy, College of Medicine of the University of Lagos under standard animal housing condition of 24 ± 2 °C and 12/12 h light/dark cycle. The rats had access to standard rat chow and water *ad-libitum*. All procedures were carried out in accordance with the National Institute of Health Guide for the Care and Use of Laboratory Animals (NIH Publications No. 80-23) revised 1996. This research was approved by the Health Research Ethics Committee of the College of Medicine of the University of Lagos with protocol number CMUL/HREC/03/17/113. The animals were randomly divided into seven groups (Control, DMSO, Nar. Quer, cART, cA/N, and cA/Q) of 10 animals each. The control group received 1 ml distilled water; DMSO group received 1% v/v of Dimethyl Sulfoxide, while cART group received 24 mg/kg cART (Tenofovir 300 mg + Lamivudine 300 mg + Efavirenz 600 mg) ([@bib0280]); Nar received 50 mg/kg Naringenin ([@bib0150]); Quer received 50 mg/kg Quercetin ([@bib0040]); Group cA/N received a mixture of 24 mg/kg cART and 50 mg/kg Naringenin; Group cA/Q received a mixture of 24 mg/kg cART and of 50 mg/kg body weight of Quercetin. cART was dissolved in distilled water while the rest of the experimental groups were dissolved in 1% v/v DMSO. Oral route of administration was used for the 56 days of treatment ([@bib0005]).

2.3. Animal sacrifice and sample collection {#sec0025}
-------------------------------------------

At the end of the experiment, all the animals were euthanized, using urethane ([@bib0145]). The hippocampus of the rats (n = 5) were dissected on an ice stage and preserved at −80 °C for oxidative stress markers and TNF-α analysis. Other animals (n = 5) for immunohistochemistry of Monoamine oxidase-B (MAO-B) and basic histology (H and E stain) were perfused with 10% neutral buffered formalin, the whole brain was fixed in the same fixative.

2.4. ELISA {#sec0030}
----------

For the preparation of oxidative stress markers and TNFα, 0.5 *g* of the hippocampus was homogenized using tissue homogenizer in 4.5 ml of 0.4 M sodium phosphate buffer (pH 7.0), centrifuge at 3500 rpm for 10 min and the supernatant removed for the assay.

### 2.4.1. Assessments of total protein, superoxide dismutase (SOD), catalase (CAT) and reduced glutathione (GSH) in hippocampus {#sec0035}

Total protein was first determined by Biuret methods. In the Biuret reaction, the cupric ions in the reagent join with the peptide bonds of the protein molecules in an alkaline solution to form a blue-violet coloured complex. Briefly, for each sample, 1.0 ml of biuret reagent (test) and 1.0 ml of blank reagent (reagent blank) were pipetted into test tubes. 0.02 ml (20 μl) of each sample was added to the test and 20 μl water to the blank. A standard test tube was also set up for each batch and contained 20 μl of standard protein 1.0 ml of biuret reagent. This was mixed and allowed to stand at room temperature for 30 min. The instrument was zeroed with the reagent blank solution and the absorbance of the test and the standard was measured at 546 nm wavelength.

Total SOD activity in tissue homogenates was determined following the procedure of [@bib0170] with some modifications. The method is based on the ability of SOD to inhibit the autoxidation of pyrogallol. 970 μL of buffer (100mMTris−HCl, 1 mM EDTA, pH 8.2), 10 μL of homogenates and 20 μL pyrogallol (13 Mm) were mixed. Assay was performed in cuvettes at 25 °C for 5 min and changes in absorbance per minute were recorded using a spectrophotometer at 480 nm.

Catalase (CAT) was expressed as moles of hydrogen peroxide (H~2~O~2~) consumed/min/mg protein. The reaction mixture (1.5 ml) contained 1.0 ml of 0.01 M pH 7.0 phosphate buffer and 0.4 ml of 2 M H~2~O~2~. Assay was performed in cuvettes at 25 °C for 3--5 minutes and changes in absorbance per minute were recorded using a spectrophotometer at 620 nm. ([@bib0230]).

Reduced glutathione (GSH) was determined by the method described by [@bib0080]. To the homogenate was added 10% Trichloroacetic acid (TCA) (equal volume) and centrifuged. 1.0 ml of supernatant was treated with 0.5 ml of Ellman's reagent (19.8 mg of 5, 5′-dithiobisnitro benzoic acid (DTNB) in 100 ml of 0.1% sodium nitrate) and 3.0 ml of phosphate buffer (0.2 M, pH 8.0). The absorbance was read at 412 nm.

### 2.4.2. Determination of Lipid Peroxidation (LPO) through assessment of Malondialdehyde (MDA) in hippocampus {#sec0040}

The assay for membrane lipid peroxidation (LPO) was done in accordance with some modifications from [@bib0245]. The reaction mixture in a total volume of 3.0 ml contained 1.0 ml tissue homogenate, 1.0 ml of TCA (10%), and 1.0 ml TBA (Thiobarbituric acid) (0.67%). All the test tubes were placed in a boiling water bath for a period of 45 min. The tubes were shifted to ice bath and then centrifuged at 2500×g for 10 min. The amount of Malondialdehyde (MDA) formed in each of the samples was assessed by measuring the optical density of the supernatant at 532 nm. The results were expressed as the nmol MDA formed/gram tissue by using a molar extinction coefficient of 1.56 × 10^5^ M^−1^ cm^−1^. With the help of formula$$\text{LPO} = \frac{\text{Vol}\text{.of}\,\text{assay} \times \text{O}\text{.D} \times 10^{9}}{1.56 \times 10^{5} \times 10^{3}\text{gm}\,\text{tissue}}$$

### 2.4.3. Tumor Necrosis Factor Alpha (TNF-α) analysis in hippocampus {#sec0045}

TNF-α assay was determined using rat specific Elabscience enzyme immunoassay (ELISA) kit with a catalog No: E-EL-R0019 in accordance with manufacturer\`s instructions. Briefly, the cells inoculated in 24-well-plates were treated with 20 μg/ml SEB (24 μl/well) or 24 μl/well PBS for 36 h and centrifuged at 200×g for 5 min. The supernatants were transferred to 96-well-plates (100 μl per well) and incubated at 37 °C for 90 min. Afterward, 100 μl of biotinylated detection antibody was added and incubated at 37 °C for 1 h. The wells were aspirated and washed thrice, and 100 μl of HRP conjugate was added and incubated at 37 °C for 30 min. The wells were subsequently washed five times, and 90 μl substrate solution was added and incubated at 37 °C for 15 min. Then, 50 μl of the stop solution was added. The OD of each well was determined by using a spectrophotometer (Molecular Devices) at 405 nm. The concentration of TNFα was calculated as picogram per milliliter (pg/ml) on the basis of the standard curve.

2.5. Tissue processing for microscopic study {#sec0050}
--------------------------------------------

The tissue samples were fixed in 10% neutral buffered formalin and processed for histology and immunohistochemistry via paraffin embedding after which they were sectioned at 4 μm using a Thermo Scientific HM 325 rotatory microtome (CE Bright Company Ltd. Huntington England), cleared in xylene and hydrated in decreasing alcohols, stained with Hematoxylin and Eosin (H&E) and mounted with DPX ([@bib0065]). The histological specimen were captured and examined using the Leica SlidePath Gateway LAN software.

2.6. Immunohistochemical (IHC) analysis {#sec0055}
---------------------------------------

Brain tissues were taken from 10% neutral buffered formalin and transferred to 70% ethanol. They were then processed using a graded ethanol series and embedded in paraffin. The paraffin sections were cut into 4 μm-thick slices using a microtome (Microm HM 315 microtome, Walldorf, Germany). The processed and sectioned tissues were dewaxed with 2 changes of xylene and hydrated with decreasing grades of alcohol, and water. The slides were kept in a coplin jar containing a solution of sodium citrate (pH 6.0) before being transferred into the water bath at 95 °C. Tissue sections were washed in wash buffer, blocked with peroxidase and incubated with diluted MAO-B (clone orb157846) (Biorbyte USA) used at 1:200 dilution and incubated for 1 h at room temperature. The secondary antibody UltraVision™ Quanto Detection System HRP - Thermo Fisher Scientific detection kit (USA) was incubated for 25 min at room temperature, DAB and counterstained in hematoxylin, washed in wash buffer, dehydrated, cleared and mounted on DPX. The sections were viewed and photographed using a Leica microscope (DM 750, Germany) and an ICC HD 50 camera. Images were captured at a magnification of x400.

### 2.6.1. Percentage immunoreactivity {#sec0060}

Image analysis and capturing was done using ImageJ 1.51J8 software (NIH, USA). At least six fields of view per slide were randomly selected and captured using a 40X objective. MAO- B expression was determined as percentage of immunostaining (brown) within the field using methods in accordance with the report of [@bib0165].

2.7. Morphometry {#sec0065}
----------------

The primary aim was to estimate the volume of pyknotic neurons within the hippocampus. Pyknotic neurons were defined as neurons with chromatin condensation, often with a slightly irregular contour. The cytoplasm appears compact, and some the cells gradually lose connections with adjacent cells, and finally, they appear to be floating ([@bib0120]). This was done by adapting the methods reported by [@bib0125] and [@bib0010]. Six microscopical fields (at x400) per section, from 4 different sections were randomly chosen for analysis. The fields were sampled as images captured on a Leica DM750 brightfield microscope (Germany) via LAZ software. Volume density of the pyknotic neurons were determined by randomly superimposing a transparent grid comprising 35 test points arranged in a quadratic array. Test points falling on pyknotic neurons were summed over all fields from all sections. The total number of points divided by the total number of points hitting on the hippocampus section multiplied by 100, provided an unbiased estimate of its %volume density/volume fraction.

2.8. Behavioral studies: Morris Water Maze (MWM) {#sec0070}
------------------------------------------------

Cognitive evaluation for neurodegenerative behavior was done using Morris Water Maze (MWM) test in accordance with ([@bib0070]). The MWM is used to assess learning and recollection ability of rats involving the use of exploratory, navigational, spatial and contextual memory ([@bib0270]; [@bib0110]). The hidden platform version of MWM is a test of spatial memory which is sensitive to hippocampal damage. It consisted of a circular pool (1 m in diameter and 50 cm in height) of tepid water and a hidden platform was constructed of transparent plastic (11 × 11 cm and a height of 18 cm). Rats (n = 5) were trained for seven days from the 50th day of treatment to use visual cue to locate an escape platform hidden above (1 cm) the surface of the water. The first three days (50th-52nd) were initial spatial training with a visible platform, During each trials, rats were required to swim to find a hidden platform for about 60 s and rats that failed to locate the hidden platform on time were guided towards the platform and were allowed to rest on the platform for about 20 s before being returned to their cage. Rats were trained in the initial spatial learning task for 4 trials per day with 10 min inter-trial intervals for 3 consecutive days for them to be familiar with the pool. During each trial, rats were allowed to swim until they found the hidden platform where they remained for 20 s before being returned to their cages.

Days 53--55 of treatment were reversal training, after the initial spatial learning task, a reversal learning protocol was conducted with some rats. During reversal learning, the hidden platform was moved to the opposite quadrant. Reversal learning entailed 3 additional days with 4 trials per day, again with a visible platform and their swim path time was recorded. On the 56th day of treatment, four trials were conducted using an invisible platform. Twenty-four hours after the final reversal training trial, rats were returned to the pool from a novel drop point with the hidden platform absent for 60 s and their swim path time (latency) away from the initial positions of the platform was recorded. Theoretically, control animals would navigate towards the position of the hidden platform within a shorter time compared to animals that have cognitive impairments.

2.9. Statistical analysis {#sec0075}
-------------------------

The values for the results were expressed as mean ± standard deviation (SD). All Statistical level of significance except otherwise stated were determined using one-way analysis of variance (ANOVA) with Tukey's post hoc test on a Graph pad Prism 5 (Graph Pad software). The mean difference was significant at 95% confidence interval (*p* \< 0.05). The unbiased stereology was done using a two-way ANOVA and bonferorri posthoc test. The MWM behavioral data were expressed as the average number of seconds taken to find the platform per trial or per day ([@bib0035]). The data from MWM were subjected to a test for normality which was conducted using the D'Agostino & Pearson omnibus normality test and found to have a Gaussian distribution.

3. Results {#sec0080}
==========

3.1. Oxidative stress markers and tumor necrosis factor alpha {#sec0085}
-------------------------------------------------------------

There was a significant decrease in the SOD of animals that received Naringenin compared to control (*p* \< 0.0001) and compared to DMSO (*p* \< 0.001). SOD also significantly decreased in animals that received cART compared to control (*p* \< 0.001) but increased significantly in the group that received cART with quercetin compared to control (*p* \< 0.001), DMSO (*p* \< 0.0001), and cART (*p* \< 0.0001). Animals that received a combination of cART and Naringenin also had a significant increase (*p* \< 0.001) in SOD compared to cART only ([Fig. 1](#fig0005){ref-type="fig"}a).Fig. 1Showing Oxidative stress markers and Tumor necrosis factor alpha (TNFα). \**p* \< 0.05 compared to control; ^α^*p* \< 0.05 compared to cART; ^αα^*p* \< 0.001 compared to cART, ᶞ*p* \< 0.05, ᶞᶞ*p* \< 0.001, ᶞᶞᶞ*p* \< 0.0001 compared to DMSO (n=5). Figures are represented as mean ± SD.Fig. 1

[Fig. 1](#fig0005){ref-type="fig"} There was a significant increase in catalase level in animals that received quercetin only compared to control (*p* \< 0.0001) and those that received naringenin only compared to DMSO (*p* \< 0.05). There was also a significant increase (*p* \< 0.0001) of catalase in animals that received both cART and quercetin compared to those in cART only group ([Fig. 1](#fig0005){ref-type="fig"}b).

There was a significant increase in GSH of animals that received quercetin compared to control (*p* \< 0.001) and compared to DMSO (*p* \< 0.0001). The animals that received a combination of cART and quercetin also had a significant increase (*p* \< 0.0001) in GSH compared to those that had cART only ([Fig. 1](#fig0005){ref-type="fig"}c).

There was a significant increase in MDA levels of animals that received cART (*p* \< 0.0001), quercetin (*p* \< 0.001), and a combination of cART and quercetin (*p* \< 0.001) compared to control. There was also a significant increase (*p* \< 0.001) in animals that received quercetin compared to DMSO. It was also observed that MDA decreased significantly (*p* \< 0.0001) in animals that received both cART and naringenin compared with those that received cART only. ([Fig. 1](#fig0005){ref-type="fig"}d).

There was a significant increase (*p* \< 0.05) in TNF-α in quercetin compared to DMSO. The other groups had no significant difference in comparison with control or cART ([Fig. 1](#fig0005){ref-type="fig"}e).

3.2. The cyto-architecture of the hippocampus {#sec0090}
---------------------------------------------

The normal neuronal pyramidal cells in the dentate gyrus, the Cornus Ammonis of the control group. The Histology of the dentate gyrus ([Fig. 2](#fig0010){ref-type="fig"}) showed marked degenerative changes including shrinkage of the cytoplasm, extensively dark pyknotic nuclei (black arrows) and increased ferrugination of the neurons in the internal granule cells of animals administered cART only, and DMSO compared to other groups. Though there were slight degenerative changes observed in the group that received Naringenin only, and both Naringenin and cART simultaneously, there were still more normal neuronal cells in this group when compared to the DMSO, and cART only ([Fig. 4](#fig0020){ref-type="fig"}a).Fig. 2Dentate gyrus in the hippocampus of rats. Groups Control, Nar, Quer, cA/N, and cA/Q show normal histology with very few marked pyknotic neurons (red arrows). DMSO and cART show marked shrinkage of the cytoplasm, pyknotic nuclei and ferrugination of neurons (red arrows) (n = 5).Fig. 2

The same findings were observed in cornus ammonis area 3 (CA3) ([Fig. 3](#fig0015){ref-type="fig"}). Animals that received 1% v/v DMSO had cellular shrinkage, pyknotic nucleus and ferrugination of pyramidal cells in the fascia dentate and CA3 compared to control group. There were also few pyknotic nuclei found in Naringenin and quercetin groups.Fig. 3Cornu ammonis area 3 (CA3) of hippocampus. Control: showing normal neurons (black arrows); DMSO: presence of pyknotic nuclei (red arrows). cART: multiple pyknotic nuclei and increased mineralization in soma bodies (red arrows); Nar, Quer, cA/N and cA/Q show normal cytoarchitecture with very few pyknotic nuclei (n = 5).Fig. 3Fig. 4Immunohistochemistry of Monoamine oxidase B (MAO- B) expression seen in the brown stains x400 (left), x1000 (right) (n = 5).Fig. 4

3.3. Immunohistochemistry of monoamine oxidase (MAO-B) {#sec0095}
------------------------------------------------------

There was a significant (*p* \< 0.05) increase in MAO- β expression in animals that received cART only compared to control. There was no significant difference in MAO- β expression between control and animals in the groups that received DMSO, Naringenin, and Quercetin. However, those animals that received cART and quercetin significantly (*p* \< 0.001) decreased compared to cART group. ([Fig. 4](#fig0020){ref-type="fig"}b).

3.4. Neurobehavioral test {#sec0100}
-------------------------

### 3.4.1. Initial spatial memory test {#sec0105}

On comparison of the post-initial spatial training, there was a significant (*p* \< 0.0001) increase in DMSO (44.50±4.20) and cART (53.50±2.52) compared to control (37.75±1.71). The animals that were co-administered cART with either Naringenin (39.75±1.71), or quercetin (36.75±2.75) decreased significantly (*p* \< 0.0001) in spatial memory compared to animals that received cART only, and those that received cART+quercetin decreased significantly (*p* \< 0.001) compared to DMSO. ([Fig. 6](#fig0030){ref-type="fig"}a).

### 3.4.2. Spatial reversal memory test {#sec0110}

There was a significant decrease between control animals and animals treated with cART only, and quercetin (*p* \< 0.0001, *p* \< 0.05 respectively). However, when compared to the cART only group, there was a significant decrease in spatial reversal memory in animals that received both cART and Naringenin (p\<0.001), and cART and quercetin (p\<0.05) ([Fig. 6](#fig0030){ref-type="fig"}b).

### 3.4.3. Probe test {#sec0115}

There was a significant delay in the time to recognize the hidden platform in animals that received cART only, Naringenin, quercetin, (*p* \< 0.0001, *p* \< 0.05, *p* \< 0.05 respectively) compared to control. It was also observed that animals that received cART alone took longer time to recognize the platform compared to cART with Naringenin, and cART with quercetin groups ([Fig. 6](#fig0030){ref-type="fig"}c).

4. Discussion {#sec0120}
=============

In this study, the hippocampus-the cradle of cognition controlling several higher brain functions including, learning, memory, and spatial coding was studied to determine the therapeutic potential of Naringenin, and Quercetin following cART administration. Neurotoxic effects of cART was observed as evidenced in the increased MDA levels, representing a marked increase in lipid peroxidation as a result of excessive ROS production and an unopposed action by antioxidant enzymes within the hippocampus. Plausibly, cART inhibits the production of enzymatic antioxidants (GSH, SOD, and CAT) while increasing ROS leading to the induction of oxidative stress. Oxidative stress which is the biological basis for most diseases ([@bib0130]) has been linked with neuro-inflammatory response and reported to inhibit neurotransmission and synaptic plasticity ([@bib0260]). However, while the interplay between cART-induced oxidative stress and neuro-inflammation may elicit the release of cytokines, it certainly does not affect rat TNFα as observed from our results. A study by [@bib0050] reports that increase in neuroinflammation as indicated by TNFα does not necessarily connote memory impairments. Therefore, the nonresponse to TNFα in this study does not translate to lack of memory loss.

The brain is particularly susceptible to oxidative damage due to its high amounts of unsaturated fatty acids whose double bonds are radico-philic in addition to its low antioxidant defense system ([@bib0090]). Thus, triggering a cascade of deleterious reactions on neighbouring fatty acids culminating to neurodegeneration. It has been reported that the byproducts of lipid peroxidation have high affinity for amino acids, hampering glutamate and sugar uptake blocking neurotransmitters and activating c-Jun and MAP kinase pathways to invoke cellular apoptosis ([@bib0135]).

On the contrary, animals that received co-administration of cART with either Naringenin or Quercetin had improved memory compared to those with cART alone.

Furthermore, in this study, histology showed marked neurodegeneration in the hippocampal neurons as evidenced in the cytoplasm shrinkage and pyknotic nuclei in the granule cells of the dentate gyrus and CA3 regions in cART treated animals. Dentate gyrus consist of a complex neuronal circuit which acts as a gate to the propagation of limbic activities ([@bib0075]). Granule cells in dentate gyrus receive excitatory neuronal inputs from entorhinal cortex and sends it to CA3 ([@bib0295]). Therefore, it plays a critical role in both cognition and in regulation of induction and propagation of pathological activities ([@bib0055]). Increased lipid peroxidation which reduces membrane fluidity and compartmentation ([@bib0100]) most likely resulted in impaired cellular function and senescence of the granule cells ([Fig. 1](#fig0005){ref-type="fig"}). Though these effects were mitigated by Quercetin and Naringenin, it is not quite clear why naringenin alone had some deleterious effects on the histology of the hippocampus ([Fig. 5](#fig0025){ref-type="fig"} a) However, this finding could be related to the toxicity of 1% DMSO which has been reported to impair cell viability, mitochondrial integrity and glutamate transporter expression of astrocytes ([@bib0310]). This is also in concert with the report of [@bib0190]. It appears most of the toxicity Monoamine oxidase- β (MAO- β), a mitochondrial enzyme which metabolizes/inhibits dopamine neurotransmitters has been reported to enhance the production of ROS culminating in cell senescence ([@bib0160]). Though there exist some opposing views ([@bib0045]; [@bib0220]), our study tends to conform with the former. In this study, it was observed that MAO-B was expressed majorly in the synaptic cleft. Whether or not MAO-B is involved in the pathophysiology of ROS generation is not clear, however, the upregulation of MAO-B expression and the marked increase in MDA levels in addition to the decrease in antioxidant enzymes suggest that MAO-B is directly or indirectly involved with oxidative stress and subsequent neurodegeneration.Fig. 5(a) quantification of pyknotic neurons (b) Quantification of Immunohistochemistry of Monoamine oxidase B (MAO- B) expression. Values are represented as mean ± SD. \*p \< 0.05, \*\**p* \< 0.001, \*\*\**p* \< 0.0001 compared to control; ^α^*p* \< 0.05, ^αα^*p* \< 0.001, ^ααα^*p* \< 0.0001 compared to cART, ᶞ*p* \< 0.05, ᶞᶞ*p* \< 0.001, ᶞᶞᶞ*p* \< 0.0001 compared to DMSO.Fig. 5Fig. 6Neurobehavioral studies: Morris water maze test. \*p \< 0.05, \*\**p* \< 0.001, \*\*\**p* \< 0.0001 compared to control; ^α^*p* \< 0.05, ^αα^*p* \< 0.001, ^ααα^*p* \< 0.0001 compared to cART, ᶞ*p* \< 0.05, ᶞᶞ*p* \< 0.001, ᶞᶞᶞ*p* \< 0.0001 compared to DMSO (n=5). Figures are represented as mean ± SD.Fig. 6

The consequence of these neurodegenerative changes in cART-treated animals was evident in the post neurobehavioral studies. The resultant delay in initial spatial reversal and probe tests in cART-treated animals concurs with numerous studies supporting the hypothesis that oxidative stress could culminate in dementia and other memory loss diseases ([@bib0105]; [@bib0095]). Furthermore, the inhibition of dopamine in the hippocampus would inhibit synapses and transfer of excitatory information from the entorhinal cortex to the limbic system thereby resulting in memory impairments ([@bib0185]; [@bib0060]). Moreover, the numerous necrotic cells seen in the dentate gyrus and the Cornus ammonis region of the hippocampus of animals treated with cART is in sync with the outcomes of the neurobehavioural studies. Whereas, loss of spatial memory and impaired learning may be due to a plethora of factors, nevertheless, the role of mitochondria-induced oxidative stress is pivotal in such neurodegenerative changes.

Thus, in pursuance of therapeutic measures, a balance in the redox reaction may be the lee way. The use of Naringenin and Quercetin -- bioflavonoids rich in antioxidants have been explored in this study to mitigate the neurodegenerative effects of cART and restore/enhance memory. Our results also clearly show a potentiation of endogenous antioxidant enzymes in the hippocampus by Quercetin and Naringenin, mitigating lipid peroxidation by neutralizing the cART-induced free radicals. This is consistent with previous reports on the rich antioxidant and free radical scavenging properties of Quercetin ([@bib0275]) and Naringenin ([@bib0020]).

Furthermore, the consequence of generating endogenous antioxidant enzymes and the ROS-neutralizing potential of these bioflavonoids (especially quercetin) is observed in the seamless neurogenesis ongoing in the dentate gyrus, as well as prevalence of pyramidal neurons in the CA3 of co-treated groups. The effect therefore, is the unattenuated transmission of excitatory impulse from the hippocampus to other higher centers ([@bib0295]). Perhaps, this culminated to the improvement of spatial memory as observed in this study.

Moreover, the downregulation of MAO-B as observed in the quercetin and cART co-treated groups portrays quercetin as a MAO-B inhibitor. MAO-B inhibitors has been explored as a therapeutic intervention in chronic neurodegenerative diseases including Parkinson\`s disease ([@bib0200]). Though dopamine levels were not assessed in this study, it is plausible that quercetin prevented its metabolism allowing for good neuronal synapses.

Firm conclusions have not been reached on the bioavailability of flavonoids in the human brain, however, its ability to penetrate the BBB seem to be premised on lipophilicity of individual flavonoids/metabolites, less polar flavonoids/metabolites are capable of greater brain uptake than the more polar ones (i.e., sulfated and glucuronidated derivatives) ([@bib0305]). In addition, their brain entry is dependent on their interactions with specific efflux transporters (such as P-glycoproteins) located in the BBB ([@bib0085]). Thus, flavonoids on penetrating the brain induce a cascade of reactions involving the impairment of excess ROS production. ROS has been reported to regulate the PI3 kinase signaling pathway by inhibiting the phosphatase and tensin homolog (PTEN), which in turn antagonizes the PI3k product phosphoinositide‐3‐phosphate ([@bib0140]; [@bib0175]). Flavonoids have been reported to induce phosphorylation of hippocampal PI3k/Akt, the activation downstream of mTOR, and the increased expression of activity-regulated cytoskeletal-associated protein (Arc/Arg3.1) ([@bib0290]). Such changes most likely underpin the enhancements in spatial memory, plausibly, through the downregulation of MAO-B and the upregulation of dopamine neurotransmitters facilitating changes in synaptic strength and the induction of morphological changes of the neurons ([@bib0175]).

In congruence with this allusion, the effective neuronal preservation and synaptic plasticity enhanced by Naringenin and Quercetin is seen in the improved post initial spatial tests but for the post probe test and the post reversal test, the mechanism underpinning the delayed latency remains unclear.and may require further studies.

5. Conclusion {#sec0125}
=============

In conclusion, cART increases ROS production, MAO-B expression, and impairments on spatial memory and learning. This study for the first time shows that a combination of either Naringenin or Quercetin with cART could preserve hippocampal neurons from the diverse toxicities of cART via the modulation of oxidant-antioxidant pathway.
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